GENOME CARE

Our journey at GenomeCare

2020~Present

2025

  • Selected for the SME Technology Innovation Development Program

2024

  • Launch of Precision GenoMom
  • Acquisition of GenomeCare by CytoGen
  • Launch of ora™

2023

  • Launch of GenoFind
  • Company name changed to GenomeCare Inc.
  • Export contract for GenoMom-i with CLWH LLC in Mongolia (Gwangju CL Hospital)
  • U.S. patent registered for NIPT

2022

  • Launch of GenoMom-i
  • Signed MOU with Bundang CHA Hospital for development and clinical trials of Multiplex PCR kits

2021

  • Launch and export of PCR diagnostic kits

2020

  • Launch of GenoBenet
  • Publication of research paper on AI-based fetal fraction measurement technology
  • Selected for the SME Technology Innovation Development Program

2012~2019

2019

  • Relocation to new headquarters (Gwanggyo Central Biz Tower)
  • Appointment of CEO Hong-Kye Lim
  • Signed MOU with Hallym University Sacred Heart Hospital for preterm birth risk prediction system research
  • Signed MOU with Yonsei University College of Medicine for liquid biopsy tumor tracking research
  • Signed MOU with Sejong University Big Data AI Team for neonatal genetic disorder research

2018

  • Obtained approval for PGS testing
  • Export contract for NIPT to the Middle East
  • Established corporate research institute at Ajou University
  • Technology transfer of NIPT to CHA Hospital and Cheil General Hospital
  • U.S. patent application filed for NIPT
  • Third domestic patent registered for NIPT
  • Export contract for GenoMom with Ecohealth in Vietnam

2017

  • Launch of GenoBro
  • Export contract for GenoMom with PTC in Thailand
  • Second domestic patent registered for NIPT
  • Fourth set of clinical trial results announced for NIPT

2016

  • Registered as a certified genetic testing institution
  • Registered as a venture company
  • Domestic patent registered for NIPT
  • Second and third sets of clinical trial results announced for NIPT

2015

  • Relocation of headquarters to Gwanggyo
  • Established corporate research institute
  • Launch of GenoMom service
  • Trademark registration for GenoMom service

2014

  • Publication of first clinical trial results for NIPT

2012

  • Founded Theragen GenomeCare Inc.
LIMS Access Precision GenoMom GenoBro ora™

Privacy Policy

The company informs customers through the Privacy Policy about how the personal information provided is used and what measures are taken to protect personal information.

Purpose of Collecting and Using Personal Information

- Identifying individuals, verifying real names, confirming intent to sign up, and ensuring age-restricted service usage based on service use.
- Fulfilling contracts related to service provision, such as billing for services provided, delivering content, purchasing and processing payments, and dispatching items or billing statements.
- Delivering notices, ensuring communication for handling complaints, and ensuring accurate delivery information for item shipments.
- Providing information on new services and offering personalized services.
- Facilitating smooth provision of high-quality services.

Personal Information Collected

- Name, company name, email, address, contact number, mobile phone number, inquiry details, and other optional items.

Retention and Use Period of Personal Information

- As a general rule, personal information is destroyed immediately once the purpose for its collection or provision has been fulfilled.
- However, for the purpose of ensuring smooth service consultations, the content of the consultation may be retained for 3 months after completion. In cases where other laws, such as the Act on the Consumer Protection in Electronic Commerce, require preservation, the information may be retained for a specified period.

Procedure and Method for Destroying Personal Information

The company, as a general rule, destroys personal information without delay after the purpose of collection and use has been fulfilled. Information entered for membership or other purposes is transferred to a separate database (or, in the case of paper records, to a separate file) and stored for a certain period according to internal policies and relevant laws before being destroyed. Personal information transferred to a separate database is not used for any other purpose unless required by law. Personal information stored in electronic file formats is deleted using technical methods that prevent the recovery of the records.

Refusal of Unauthorized E-mail Collection

GENOMECARE prohibits unauthorized email collection.

The collection of email addresses posted on this website using email collection programs or other technical devices is prohibited, and violators may be punished under the Act on Promotion of Information and Communications Network Utilization and Information Protection.